Hypertension
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) The studies are case-control studies, cohort studies, and randomized clinical trials. (2) The studies are of patients with clinically diagnosed hypertension. (3) It includes a normotensive group as a control. (4) The study describes the complication of malignancy.
Exclusion criteria
Exclusion criteria: We will examine whether cancer risk is higher in people with hypertension. Drug use and cancer risk, such as antihypertensive medications, will be excluded. The search will be limited to solid tumors because blood cancers are rare in this topic. In addition, the following items will be used as exclusion criteria. (1) Systematic review or meta-analysis articles. (2) Case reports or case series reporting less than 50 cases. (3) The republished research literature is excluded unless the research includes new findings related to malignancy outcomes. (4) Studies published in languages other than English.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the risk of developing solid tumors in hypertensive patients. Hazard ratios (HRs) will be calculated for the incidence of solid tumors in hypertensive patients and normotensive patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is the risk of developing solid tumors in untreated hypertensive patients. | — |
Countries
Japan
Contacts
Public ContactShintaro Minegishi
Yokohama City University Graduate School of Medicine Department of Cardiology
Outcome results
None listed